Cherie Champagne, MD
Interventional Cardiology · Gulfport, MSNPI 1720432107
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,632 of the $9,183 with a category attached, or 72.2%. 32 manufacturers reported payments, led by Medtronic at 27.3% of the total.
Across 234 payments — averaging $39.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$1K
- Boston Scientific$1K
- Penumbra, Inc.$965
- E.r. Squibb & Sons, L.L.C.$440
- Abiomed$392
- plus $2K from 26 others
What the payments were for
- Travel & lodging$2,40226%
- Food & beverage$6,63272%
- Education$1492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 37 | $2,507 |
| Abbott | 24 | $1,478 |
| Boston Scientific | 19 | $1,117 |
| Penumbra, Inc. | 16 | $965 |
| E.r. Squibb & Sons, L.L.C. | 22 | $440 |
| Abiomed | 25 | $392 |
| Shockwave Medical, Inc | 2 | $197 |
| Inari Medical, Inc. | 9 | $195 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $193 |
| Lexicon Pharmaceuticals, Inc. | 7 | $191 |
| GE HealthCare | 5 | $167 |
| Amgen | 5 | $154 |
| Surmodics, Inc. | 3 | $140 |
| Baxter Healthcare | 6 | $138 |
| Stryker | 4 | $111 |
| AstraZeneca | 2 | $104 |
| Novo Nordisk | 4 | $96 |
| Merck | 4 | $89 |
| Pfizer | 4 | $83 |
| Novartis | 4 | $78 |
| Chiesi USA, Inc. | 4 | $69 |
| Acist Medical Systems, Inc. | 1 | $39 |
| Bayer | 2 | $33 |
| Boehringer Ingelheim | 2 | $30 |
| Angiodynamics, Inc. | 1 | $25 |
| Imperative Care, Inc | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $23 |
| Heartflow, Inc. | 1 | $23 |
| Itamar Medical Inc | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,288
- SUPERA$697
- Indigo System$662
- OPTICROSS$415
- EMBOSHIELD NAV6$174
- ONYX FRONTIER$166
- RESOLUTE ONYX$149
- WATCHMAN Access System$142
- Diamondback Coronary$132
- GENERAL - STRUCTURAL HEART$122
- CAMZYOS$120
- SelectSecure$119
- Sublime 014 Rx PTA Balloon Dilatation Catheter$112
- Sublime Microcatheter, 018, 200cm, Straight$112
- Pounce Thrombectomy System$112
- Pounce Thrombectomy$112
- Pounce Venous Thrombectomy System$112
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$103
How this compares
$9,183 in reported general payments places this provider in the 55th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $99,342 |
| EntrestoSacubitril/Valsartan | 70 | $57,676 |
| XareltoRivaroxaban | 48 | $46,312 |
| JardianceEmpagliflozin | 63 | $40,472 |
| FarxigaDapagliflozin Propanediol | 28 | $23,668 |
| Repatha SureclickEvolocumab | 19 | $16,721 |
| BrilintaTicagrelor | 14 | $11,242 |
| Praluent PenAlirocumab | 14 | $6,840 |
| Metoprolol Succinate | 264 | $2,803 |
| Rosuvastatin Calcium | 177 | $1,260 |
| Amiodarone Hcl | 57 | $1,228 |
| Carvedilol | 220 | $1,098 |
| ClopidogrelClopidogrel Bisulfate | 123 | $889 |
| Atorvastatin Calcium | 145 | $869 |
| Losartan Potassium | 124 | $634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $99,342113 claims |
| NovartisEntresto | $78 | $57,67670 claims |
| Johnson & JohnsonXarelto | $18 | $46,31248 claims |
| Boehringer IngelheimJardiance | $30 | $40,47263 claims |
| AstraZenecaFarxiga, Brilinta | $104 | $34,91042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Gulfport
- John WinscottJackson$482K
- William CrowderJackson$331K
- Foluso FakoredeCleveland$298K
- James BennettJackson$160K
- Abdul BahroFlowood$132K
- Brett BennettJackson$126K
- John KingColumbus$74K
- Michael CunninghamBiloxi$45K
- Alejandro Lemor FerrandJackson$37K
- David YoungJackson$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.